MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Unveiling the Role of Butyrylcholinesterase in Hepatic Fibrosis: A Novel Cholinergic Target in Liver Disease

MedXY Editorial Team•Sep 28, 2026•Gastroenterology
liver fibrosisButyrylcholinesterasehepatic stellate cellsmuscarinic signaling

Highlight

• Butyrylcholinesterase (BuChE) expression and activity are markedly reduced in fibrotic liver disease, correlating with fibrosis severity.
• Hepatocyte-derived BuChE enzymatic activity limits hepatic stellate cell (HSC) activation by metabolizing acetylcholine (ACh), preventing paracrine cholinergic signaling.
• Loss of BuChE leads to ACh accumulation, triggering HSC activation through muscarinic receptor M3 (ChRM3)-NF-κB signaling and promoting fibrogenesis.
• Targeting BuChE-ACh-ChRM3 axis presents a promising therapeutic strategy to modulate fibrosis progression in chronic liver diseases.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLDThis article reviews evidence linking cardiovascular-kidney-metabolic syndrome stages to liver fibrosis severity, progression, and liver-related events in metabolic dysfunction-associated steatotic liver disease (MASLD). Higher CKM stages iAug 14, 2026Disentangling Weight Loss-Dependent and Independent Effects of Survodutide on Liver Outcomes in MASH: Insights from a Phase 2 Mediation AnalysisThis mediation analysis of a phase 2 MASH trial reveals that survodutide improves liver inflammation and fibrosis predominantly through weight-independent mechanisms, highlighting a potential direct hepatic effect beyond weight reduction.Aug 4, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
pFIB Scores for Pediatric MASLD Fibrosis Linked to Risk of Youth-Onset Type 2 Diabetes in Children with Obesity
A liver fibrosis risk score (pFIB-6) identifies children with obesity at markedly increased short-term risk of type 2 diabetes, offering a potential tool for early risk stratification.
Jul 25, 2026
Global Variability in Non-Invasive Testing Accuracy for MASLD: Key Findings from the G-MASLD StudyThe G-MASLD study evaluated the diagnostic accuracy of non-invasive fibrosis tests across 41 countries, revealing regional variability and identifying Agile-3+ and Agile-4 as the most accurate for advanced fibrosis and cirrhosis in MASLD paJul 16, 2026
Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen SpeciesThis article explores the mechanism by which HBV induces liver fibrosis through pyruvate-dependent ROS production and PPARα inhibition, highlighting novel therapeutic targets for chronic hepatitis B management.Jul 10, 2026